The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
about
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and VomitingRecent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewCheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomitingManagement of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.Neuropharmacology and management of chemotherapy-induced nausea and vomiting in patients with breast cancer.Chemotherapy-induced nausea and vomiting #285.Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy.Media Reporting of Practice-Changing Clinical Trials in Oncology: A North American Perspective.Olanzapine and Betamethasone Are Effective for the Treatment of Nausea and Vomiting due to Metastatic Brain Tumors of Rectal Cancer.Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.The safety of olanzapine in young children: a systematic review and meta-analysis.Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature.Safety and efficacy of commonly used antiemetics.Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.State of the Art Antiemetic Therapy for Cancer Patients.The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department.Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer.Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.Newest Drugs for Chronic Unexplained Nausea and Vomiting.Central Aspects of Nausea and Vomiting in GI Disorders.2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy.Supportive Treatments for Patients with Cancer.2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement.Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy.Risk factors and treatment for steroid-related mood and behavior symptoms in preschool children with leukemia: A case series.A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.Analysis of Dietary Intake during Consecutive-Day Chemotherapy for Bone and Soft-Tissue Sarcomas.Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
P2860
Q26784070-188233D2-3EA6-4310-9436-5F4D5A94A8F6Q28081186-226671BB-5CDF-4D17-A3E3-9A4BEFC98965Q33866119-5B2DC070-5356-4029-B5AE-6657F7753AB5Q33886138-ECEC06C9-1C5A-4257-A1FF-7FDE687838D1Q34327488-61C8F74C-AAD3-42BD-90F3-9224ECD5F235Q34403552-DF87B525-017B-414D-A19F-48700A392E84Q34719140-5744ECA0-3427-4533-A639-F5B0581099C6Q36070497-48BE677B-FC0C-4343-9348-84AF2824CAF5Q36673522-14A41C2A-2BEE-4DBF-8941-43CB9FACDE1BQ37603154-53DB4B5D-9C1F-4DB2-9E00-CF68D1651C7CQ37730595-509F964A-F3E7-44FA-83BF-D94FFBC4A49EQ38187578-C7C92BDC-233F-4895-9EDB-C986B9CF5309Q38242011-A239BCB0-E957-4153-8EAE-A6DEA6B2466FQ38533535-E3420C04-B6A2-47A2-A8A7-9132FB5C6C0CQ38570496-19B60274-0D01-4CA4-BBF7-F098B53F6236Q38574240-A0BAC7E8-8FDD-45A5-9A83-F2F7D4621071Q38653463-B6ADED6A-F6F3-490C-AD11-574EF93610C5Q38676452-B3C110BF-9D3C-45DA-A440-10494B787B3EQ38677762-9EB9AAA8-072B-4B47-8469-884975B6CE5EQ38683885-676E7275-1F5C-4DE0-928D-76E997897E6FQ38696953-531A6864-4257-4E0E-A254-70554B56A8C6Q38739169-F65B48CC-27EE-4D69-A0A9-82A34DAE0E2CQ38767176-221CE3A1-7DE7-4236-8C3A-01DA122F1F93Q38927030-6E77AD4D-433C-4B9A-AE5E-43CF64E5CC2CQ38977503-FD7CEC18-07F3-42CB-879E-0C0849C94C8DQ38979261-75A2046D-01F4-47F0-BECE-21A6216EA1FFQ38999263-9B39CF06-8582-4C66-B945-CB6B2F14C41AQ39005867-24F01EF6-61F7-440C-9340-D1D7C68E6A14Q39137612-1D6EE11A-8F20-48E6-A3A9-A27FBBD6AF1DQ39160097-925FABAA-7E05-4FA2-AB04-A189DBAE424BQ41270171-BD031F8E-09FC-4623-AB7B-4C296E8B83CDQ46355232-079B3AC0-4909-4895-BCEE-65A3FCA22792Q47135544-E025E25E-C475-4999-82FC-FCEE5F4E147FQ47296270-4F98D7C9-E639-40B2-9757-77488C60BD33Q47661123-0471BACF-D382-4D05-AD8B-24229B7B2FC3Q47741649-E6EE1DDD-4E18-42FF-BB07-A5E4C9591EDDQ47856901-16F8F981-ED4F-423C-B0E0-3FB3D702BA88Q48302132-A169B998-E26E-4DB4-A772-92A3EDB37BD7Q49164451-4AE2F380-A91A-4A3A-B644-958D875F967FQ50441498-4E3A783E-B0FD-400D-8008-7413897D607C
P2860
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
The use of olanzapine versus m ...... ighly emetogenic chemotherapy.
@ast
The use of olanzapine versus m ...... ighly emetogenic chemotherapy.
@en
The use of olanzapine versus m ...... ighly emetogenic chemotherapy.
@nl
type
label
The use of olanzapine versus m ...... ighly emetogenic chemotherapy.
@ast
The use of olanzapine versus m ...... ighly emetogenic chemotherapy.
@en
The use of olanzapine versus m ...... ighly emetogenic chemotherapy.
@nl
prefLabel
The use of olanzapine versus m ...... ighly emetogenic chemotherapy.
@ast
The use of olanzapine versus m ...... ighly emetogenic chemotherapy.
@en
The use of olanzapine versus m ...... ighly emetogenic chemotherapy.
@nl
P2093
P2860
P1476
The use of olanzapine versus m ...... ighly emetogenic chemotherapy.
@en
P2093
Cindy K Nagy
Rudolph M Navari
Sarah E Gray
P2860
P2888
P304
P356
10.1007/S00520-012-1710-6
P577
2013-01-12T00:00:00Z